PHG Stock Analysis: Buy, Sell, or Hold?
PHG - KONINKLIJKE PHILIPS N.V.
$25.23
-0.27 (-1.06%)
▼
5d:
-7.28%
30d:
-11.88%
90d:
-19.26%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When PHG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PHG shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PHG shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$44.96
Based on 8.6% avg growth
INTRINSIC VALUE TODAY
$27.91
9.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHG is currently trading at $25.23, which is considered oversold relative to its 30-day fair value range of $26.22 to $28.57. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.3) compared to its historical average (14.6). Remarkably, the market is currently pricing in an annual earnings decline of 5.6% over the next few years. This pessimistic expectation contrasts with the company's recent 97.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PHG is in a downtrend. The price is currently testing key support at $25.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PHG has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $33.54 (+32.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PHG is in a downtrend. The price is currently testing key support at $25.19. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PHG has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $33.54 (+32.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$26.22 -
$28.57
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.9% below Wall St target ($33.54)
- CAUTION: 5-day price weakness (-7.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$26.22 -
$28.57
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$25.19
Resistance Level
$27.80
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.32
Wall Street Target
$33.54
(+32.9%)
Revenue Growth (YoY)
-4.7%
Earnings Growth (YoY)
97.2%
Profit Margin
5.5%
Valuation Discount vs History
-5.6% cheaper
PE vs Historical
12.3 vs 14.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.6%
(market-implied from PE analysis)
1-Year Target
$23.82
(-6%)
2-Year Target
$22.48
(-11%)
3-Year Target
$21.22
(-16%)
3-Yr Target (if PE normalizes)
(PE: 12→15)
$25.15
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 13.1%)
$65.36
(+159%)
Base:
(SPY PE: 12.3, Growth: 13.1%)
$36.49
(+45%)
Bear:
(PE: 10.5, Growth: 13.1%)
$31.02
(+23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 21.57 | Current EPS (TTM): $1.17
Bull Case
$48.59
(+93%)
Analyst growth 75.0%, PE expands to 23.7
Base Case
$44.17
(+75%)
Market implied 75.0%, PE stable at 21.6
Bear Case
$17.16
(-32%)
Severe decline -20.0%, PE contracts to 18.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.3 to 14.6
Stabilization Target:
$29.89
(+18.5%)
PE Expansion Potential:
+18.5%
Share & Embed Analysis
Last updated: May 18, 2026 5:09 AM ET
Data refreshes hourly during market hours. Next update: 6:09 AM
Data refreshes hourly during market hours. Next update: 6:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$85 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$83 | 66 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$108 | 64 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 55 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 55 HOLD |
